bullish
Cellid (299660 KS): Promising Immunotherapeutic Platform; Well-Funded to Commercialize Pipeline
338 Views15 Jun 2022 22:56
SUMMARY
- Cellid (299660 KS) is developing a rich pipeline of five cell-based anticancer therapeutic vaccines, for which there are no commercialized competing products at present. BVAC-C is the lead candidate.
- BVAC-C is being developed for cervical, head and neck, anal, and certain other cancers. It is the world's first-in-class in terms of its complex and powerful anticancer action mechanism.
- Cellid has secured government funding of KRW8.9 billion for its COVID-19 vaccine candidate. The company is accelerating clinical trial of COVID-19 booster dose candidate.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Cellid (299660 KS): Promising Immunotherapeutic Platform; Well-Funded to Commercialize Pipeline15 Jun 2022
x